13 results about "Tauroursodesoxycholic acid" patented technology

A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention / suppression agent.

Provided are pharmaceutical compositions comprising a combination therapy having therapeutically effective amounts of sodium 4-phenyIbutylate and tauroursodeoxycholic acid for the treatment of an ocular condition in a subject. Also provided herein are methods using the combination therapy, and a pharmaceutical composition thereof, for preventing or treating an ocular condition in a subject.

The invention provides bile acid for improving microgravity-induced glucose metabolism disorder and application of the bile acid, and belongs to the technical field of medicines. According to the invention, tauroursodeoxycholic acid (TUDCA) is utilized to effectively reduce the blood glucose level of a microgravity environment model mouse, improve the liver glucose metabolism function and inflammation state of the microgravity environment model mouse, and reduce the serum cholesterol level of the model mouse; a technical scheme which is high in safety and clear in targeting and has application potential is provided for intervention of metabolic abnormalities in the microgravity environment, and an experimental foundation is laid for development of related functional products or protective preparations.

This invention discloses genetically engineered bacteria and their applications, belonging to the field of bioengineering technology. By constructing a system that enhances the expression of polyphosphate kinase 2-I, polyphosphate kinase 2-II, and peptide bond synthase, this invention establishes an ATP recycling system, effectively ensuring the continuous execution of enzyme-catalyzed reactions. Using ursodeoxycholic acid or glycine and taurine as substrates, the genetically engineered bacteria expressing these three enzymes generate tauroursodeoxycholic acid or glycoursodeoxycholic acid, increasing the yield of these enzymes and achieving efficient biosynthesis of tauroursodeoxycholic acid or glycoursodeoxycholic acid, demonstrating promising prospects for industrial application.

The invention relates to the field of biology, in particular to application of tauroursodeoxycholic acid in preparation of a medicine for promoting function maturation of islet organs. The specific effect of tauroursodeoxycholic acid in promoting functional maturation of iPSC-derived islet-like organs is found and verified for the first time, and a brand new treatment thought is represented. The beta cell functional gene expression and glucose stimulation response capability of the sc-islet can be remarkably improved only by performing TUDCA treatment for 96 hours, and the function maturation period is greatly shortened. The obvious effect can be achieved by adopting the low-dose TUDCA with the concentration of 25-100 ng / mL, the cost is reduced, and the potential toxicity risk is reduced. Key indexes (functional gene expression and glucose response) of beta cell maturation are directly targeted, and a high-quality cell model is provided for research and treatment of diabetes mellitus.

This invention discloses the application of tauroursodeoxycholic acid (TUDCA) in inhibiting α-glucosidase activity, belonging to the field of biotechnology. The invention utilizes porcine bile salts and bear bile powder for in vitro α-glucosidase inhibition experiments, performs molecular docking simulations on the components, and screens multiple bile acids for α-glucosidase inhibition, ultimately identifying TUDCA as the experimental material. Furthermore, in vivo and in vitro experiments were conducted to study the effects of TUDCA on α-glucosidase, revealing that TUDCA can significantly inhibit α-glucosidase activity and alleviate insulin resistance, classifying it as an anti-competitive inhibitor. This invention provides a novel raw material for inhibiting α-glucosidase activity, which can be applied to α-glucosidase activity inhibitors or drugs for alleviating insulin resistance.

The invention provides application of tauroursodeoxycholate in prevention or treatment of mitochondrial encephalopathy, and belongs to the technical field of medicine. The core of the invention lies in that the pathological mechanism of the mitochondrial encephalopathy is coped with by utilizing multiple biological effects of the TUDCA. In-vivo and in-vitro experiments find that after a cKO mouse is treated by TUDCA, the expression of an endoplasmic reticulum stress marker Atf4 and fatty acid synthase (Fasn) in the mouse can be remarkably reduced, and abnormal accumulation of lipid is reduced, so that the metabolic state of cells is improved. In animal models, treatment with TUDCA not only alleviates dyskinesia, but also promotes the neurogenesis process and extends the survival time of mice.

The invention discloses a method for preparing a product with a controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid, the product with the controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid and application of the method, and belongs to the technical field of biology. According to the method, the alpha-type enzyme, the lactic dehydrogenase and the beta-type enzyme are adopted to convert a reaction substrate containing taurochenodeoxycholic acid into a product with a controllable ratio of TUDCA to TCDCA through a multi-path enzymatic reaction, and the method has a relatively high application value.

A subject is administered an amount of an active agent effective to treat and / or prevent a neurological disorder, wherein the active agent comprises S-hydroxychloroquine with an enantiomeric excess of at least 20% of the S-enantiomer of hydroxychloroquine. The active agent may further comprise tauroursodeoxycholic acid and / or 3,3'-diindolylmethane. The subject may be diagnosed with a neurological disorder or may be identified as being at risk of developing a neurological disorder. Administering the active agent may at least partially normalize an aberrant level of an indicator characteristic of the neurological disorder.

The invention relates to the technical field of genomics and metabonomics, in particular to a substance for relieving intestinal injury of crisp tilapia and an application effect analysis method of the substance. According to the invention, the tauroursodeoxycholic acid (TUDCA) is applied to relieving intestinal inflammation damage caused by feed embrittlement of the crisp tilapia for the first time, and intestinal inflammation is relieved. By establishing a three-dimensional evaluation system of'intestinal histomorphology + metabonomics + metagenomics', the relieving effect of TUDCA on intestinal inflammation is systematically quantified. Through combined analysis of intestinal metabolome and metagenome, a'microorganism-host interaction 'health judgment model is constructed, and the maintenance of the quality of fish meat after inflammation is relieved is verified through muscle texture parameters, so that a'repair-evaluation-quality maintenance' closed-loop technical scheme is formed.

The present application relates to the fields of medicine, biotechnology and clinical critical medicine, and specifically discloses application of tauroursodeoxycholic acid or pharmaceutically acceptable salt, derivative or precursor thereof in preparation of a drug for improving intestinal barrier function and prognosis of a patient with sepsis. The present application discloses for the first time a molecular mechanism of TUDCA for protecting intestinal barrier function by regulating a signal axis of intestinal flora-Coriolic acids-PPARbeta-ILK, and TUDCA significantly improves the integrity of intestinal barrier by restoring intestinal flora balance, inhibiting generation of harmful metabolite Coriolic acids and activating the PPARbeta-ILK signal pathway. In the treatment of sepsis, TUDCA not only helps to repair the intestinal barrier, but also can improve the clinical prognosis of the patient, reduce the level of systemic inflammation, alleviate multiple organ failure caused by sepsis, and improve the survival rate, thereby providing a new strategy for the treatment of sepsis.

The present invention provides berberine tauroursodeoxycholate (BTUDC), pharmaceutical compositions and methods of use thereof for the treatment, amelioration and / or prevention of Parkinson's disease or related diseases and conditions as monotherapy or in combination with other agents or as an adjuvant. The present invention also provides pharmaceutical compositions of berberine (BBR) and tauroursodeoxycholic acid (TUDCA) and methods of use thereof for the treatment, alleviation and / or prevention of Parkinson's disease or related diseases and conditions as monotherapy or in combination with other agents or as an adjuvant.

The invention provides viscoelastic hydrogel microspheres with adjustable stress relaxation performance as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the invention, the idea of a'cell shock absorption 'strategy is realized, and the viscoelastic hydrogel microspheres with adjustable stress relaxation performance are successfully constructed. Chemical bonds in a hydrogel network are regulated and controlled through oxidation and hydrazine coupling reaction, and the hydrogel microspheres capable of absorbing impact and relieving cartilage cell ER stress induced by mechanical stress are prepared. The preparation method comprises the following steps: encapsulating cationic liposome modified with cartilage targeting peptide Wyrgrl and tauroursodeoxycholic acid (TUDCA) in a microsphere; the microsphere system not only can obviously dissipate impact force in a joint cavity and reduce vibration and pressure conduction, but also can realize continuous release of TUDCA, so that ER stress is relieved, and OA progress is delayed. According to the microsphere strategy, dual protection on cartilage injury can be realized by reducing mechanical stress and relieving ER stress, and the microsphere shows a good application prospect in the aspect of delaying osteoarthritis.